ACE2
Angiotensin-converting enzyme 2
Also known as: ACE2_HUMAN, ACEH
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BYF1
- Gene
- ACE2
- Ensembl
- ENSG00000130234
- Chromosome
- X
- Canonical length
- 805 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases and has considerable homology to human angiotensin 1 converting enzyme. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. ACE2 is known to be expressed in various human organs, and its organ- and cell-specific expression suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronavirus HCoV-NL63 and the human severe acute respiratory syndrome coronaviruses, SARS-CoV and SARS-CoV-2, the latter is the causative agent of coronavirus disease-2019 (COVID-19). Multiple splice variants have been found for this gene and the dACE2 (or MIRb-ACE2) splice variant has been found to be interferon inducible. [provided by RefSeq, Nov 2020]
Canonical amino-acid sequenceUniProt
805 residues, UniProt reviewed canonical sequence.
>Q9BYF1|ACE2
1 MSSSSWLLLS LVAVTAAQST IEEQAKTFLD KFNHEAEDLF YQSSLASWNY NTNITEENVQ
61 NMNNAGDKWS AFLKEQSTLA QMYPLQEIQN LTVKLQLQAL QQNGSSVLSE DKSKRLNTIL
121 NTMSTIYSTG KVCNPDNPQE CLLLEPGLNE IMANSLDYNE RLWAWESWRS EVGKQLRPLY
181 EEYVVLKNEM ARANHYEDYG DYWRGDYEVN GVDGYDYSRG QLIEDVEHTF EEIKPLYEHL
241 HAYVRAKLMN AYPSYISPIG CLPAHLLGDM WGRFWTNLYS LTVPFGQKPN IDVTDAMVDQ
301 AWDAQRIFKE AEKFFVSVGL PNMTQGFWEN SMLTDPGNVQ KAVCHPTAWD LGKGDFRILM
361 CTKVTMDDFL TAHHEMGHIQ YDMAYAAQPF LLRNGANEGF HEAVGEIMSL SAATPKHLKS
421 IGLLSPDFQE DNETEINFLL KQALTIVGTL PFTYMLEKWR WMVFKGEIPK DQWMKKWWEM
481 KREIVGVVEP VPHDETYCDP ASLFHVSNDY SFIRYYTRTL YQFQFQEALC QAAKHEGPLH
541 KCDISNSTEA GQKLFNMLRL GKSEPWTLAL ENVVGAKNMN VRPLLNYFEP LFTWLKDQNK
601 NSFVGWSTDW SPYADQSIKV RISLKSALGD KAYEWNDNEM YLFRSSVAYA MRQYFLKVKN
661 QMILFGEEDV RVANLKPRIS FNFFVTAPKN VSDIIPRTEV EKAIRMSRSR INDAFRLNDN
721 SLEFLGIQPT LGPPNQPPVS IWLIVFGVVM GVIVVGIVIL IFTGIRDRKK KNKARSGENP
781 YASIDISKGE NNPGFQNTDD VQTSFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ACE2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 231 nTPM
Expression across tissuesHPA
Tissue
- small intestine: 231 nTPM
- duodenum: 174 nTPM
- kidney: 82 nTPM
- gallbladder: 62 nTPM
- testis: 47 nTPM
- heart muscle: 40 nTPM
Single-cell type
- enterocytes: 265 nCPM
- vascular endothelial cells: 68 nCPM
- proximal tubule cells: 54 nCPM
- tuft cells: 35 nCPM
- cholangiocytes: 30 nCPM
- pericytes: 18 nCPM
Immune cell
- total PBMC: 0.2 nTPM
- basophil: 0.1 nTPM
- classical monocyte: 0.1 nTPM
- intermediate monocyte: 0.1 nTPM
- neutrophil: 0.1 nTPM
- non-classical monocyte: 0.1 nTPM
Brain region
- choroid plexus: 5.1 nTPM
- cerebellum: 1.7 nTPM
- medulla oblongata: 1.5 nTPM
- midbrain: 1.4 nTPM
- cerebral cortex: 1.3 nTPM
- hippocampal formation: 1.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ACE2.
Disease | AutoantibodyPubMed
Conditions in which antibodies against ACE2 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for ACE2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
38 publications
- Development of ACE2 autoantibodies after SARS-CoV-2 infection.
2021 · PLoS One · RCR 9.4 · 153 citations - The role of the brain renin-angiotensin system in Parkinson´s disease.
2024 · Transl Neurodegener · RCR 7.1 · 30 citations - Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19.
2021 · J Autoimmun · RCR 4.6 · 72 citations - Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity.
2024 · Commun Med (Lond) · RCR 3.7 · 22 citations - IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function.
2022 · JCI Insight · RCR 3.5 · 47 citations
Show 20 more of 38 total
- Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease.
2022 · NPJ Parkinsons Dis · RCR 3.2 · 37 citations - IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients.
2023 · J Med Virol · RCR 2.8 · 26 citations - Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies.
2024 · Front Immunol · RCR 2.6 · 15 citations - AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability.
2023 · Brain Behav Immun · RCR 2.5 · 18 citations - New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19.
2021 · medRxiv · RCR 2 · 35 citations - Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases.
2010 · Arthritis Res Ther · RCR 1.9 · 80 citations - IgM autoantibodies recognizing ACE2 are associated with severe COVID-19.
2020 · medRxiv · RCR 1.5 · 37 citations - Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination.
2023 · J Med Virol · RCR 1.5 · 13 citations - Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2.
2022 · Front Immunol · RCR 1.3 · 18 citations - TLR7 and IgM: Dangerous Partners in Autoimmunity.
2023 · Antibodies (Basel) · RCR 1.3 · 11 citations - Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
2020 · Transfus Apher Sci · RCR 1.3 · 28 citations - Discriminating promiscuous from target-specific autoantibodies in COVID-19.
2023 · Eur J Immunol · RCR 1.3 · 13 citations - Plasma angiotensin peptides as biomarkers of rheumatoid arthritis are correlated with anti-ACE2 auto-antibodies level and disease intensity.
2022 · Inflammopharmacology · RCR 1.1 · 11 citations - Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes.
2023 · Transfus Apher Sci · RCR 1 · 7 citations - Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy.
2022 · Neurol Res Pract · RCR 1 · 9 citations - Presence and Implications of Anti-Angiotensin Converting Enzyme-2 Immunoglobulin M Antibodies in Anti-Melanoma-Differentiation-Associated 5 Dermatomyositis.
2022 · ACR Open Rheumatol · RCR 0.9 · 10 citations - The prevalence and role of functional autoantibodies to angiotensin-converting-enzyme-2 in patients with systemic sclerosis.
2021 · Autoimmunity · RCR 0.8 · 12 citations - Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study.
2024 · Biomedicines · RCR 0.7 · 3 citations - Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection.
2024 · PLoS One · RCR 0.6 · 4 citations - Functional characterisation of the ACE2 orthologues in Drosophila provides insights into the neuromuscular complications of COVID-19.
2023 · Biochim Biophys Acta Mol Basis Dis · RCR 0.6 · 6 citations
Reference: B cellIEDB
1 publication
- Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity.
2024 · Commun Med (Lond) · RCR 3.7 · 22 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.25
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.25
- DepMap mean gene effect
- 0.14
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- angiotensin maturation
- angiotensin-mediated drinking behavior
- blood vessel diameter maintenance
- entry receptor-mediated virion attachment to host cell
- maternal process involved in female pregnancy
- membrane fusion
- negative regulation of ERK1 and ERK2 cascade
- negative regulation of smooth muscle cell proliferation
- negative regulation of transcription by RNA polymerase II
- positive regulation of amino acid transport
- positive regulation of cardiac muscle contraction
- positive regulation of gap junction assembly
- positive regulation of L-proline import across plasma membrane
- positive regulation of reactive oxygen species metabolic process
- receptor-mediated endocytosis of virus by host cell
- receptor-mediated virion attachment to host cell
- regulation of cardiac conduction
- regulation of cell population proliferation
- regulation of cytokine production
- regulation of inflammatory response
- regulation of systemic arterial blood pressure by renin-angiotensin
- regulation of vasoconstriction
- symbiont entry into host cell
- tryptophan transport
- viral life cycle
Molecular functions
- carboxypeptidase activity
- endopeptidase activity
- identical protein binding
- metallocarboxypeptidase activity
- metallopeptidase activity
- peptidyl-dipeptidase activity
- transporter activator activity
- virus receptor activity
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ACE2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ACE2 as an antibody target. Whether an autoantibody or antibody against ACE2 could matter depends on whether native ACE2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ACE2 is annotated at the cell surface, where native ACE2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ACE2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...